ZLAB vs. ELAN, SMMT, KRYS, OGN, APLS, RNA, IMVT, ACLX, MRUS, and XENE
Should you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Elanco Animal Health (ELAN), Summit Therapeutics (SMMT), Krystal Biotech (KRYS), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Avidity Biosciences (RNA), Immunovant (IMVT), Arcellx (ACLX), Merus (MRUS), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.
Elanco Animal Health (NYSE:ELAN) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
In the previous week, Elanco Animal Health had 9 more articles in the media than Zai Lab. MarketBeat recorded 15 mentions for Elanco Animal Health and 6 mentions for Zai Lab. Elanco Animal Health's average media sentiment score of 0.90 beat Zai Lab's score of 0.30 indicating that Zai Lab is being referred to more favorably in the news media.
97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 0.6% of Elanco Animal Health shares are owned by company insiders. Comparatively, 5.2% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Elanco Animal Health has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.
Elanco Animal Health has a net margin of -29.83% compared to Elanco Animal Health's net margin of -116.45%. Zai Lab's return on equity of 5.98% beat Elanco Animal Health's return on equity.
Zai Lab received 91 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 63.90% of users gave Zai Lab an outperform vote while only 54.10% of users gave Elanco Animal Health an outperform vote.
Elanco Animal Health presently has a consensus target price of $17.57, suggesting a potential upside of 36.32%. Zai Lab has a consensus target price of $58.97, suggesting a potential upside of 212.66%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts plainly believe Zai Lab is more favorable than Elanco Animal Health.
Zai Lab has lower revenue, but higher earnings than Elanco Animal Health. Zai Lab is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Summary
Elanco Animal Health beats Zai Lab on 9 of the 17 factors compared between the two stocks.
Get Zai Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
